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ABSTRACT
Objective: This study is to report a manual method to obtain 
platelet rich plasma (PRP). Methods: For this study 61 ml 
of peripheral blood was obtained and submitted to centri-
fugation at 541g for 5 min. The centrifugation separates the 
blood into three components: red blood cells, buffy coat 
and platelet rich plasma. Blood and platelet rich plasma 
samples were sent to the Hospital’s Laboratory and platelets 
and leukocytes were measured. Results: A sample of 637 
blood donors was evaluated. The platelet yield efficiency 
was 86.77% and the increase in platelet concentration factor 
was 2.89 times. The increase in leukocyte concentration 
factor was 1.97 times. Conclusion: The method described 
here produces leukocyte-rich and platelet-rich plasma with 
a high platelet and leukocyte increased factor. Level of 
Evidence IV, Controlled Laboratory Study.
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INTRODUCTION
Platelet-rich plasma (PRP) was first described by Whitman et al.1 
in 1997 as a derivative of fibrin glue made  by Matras,2 and today 
its use has been widely documented in the medical and dentistry 
literature.3-5 Dental surgeries, plastic surgeries, as well as ortho-
pedics, have shown good results with the use of PRP to obtain 
better healing.3-12 Although most reported positive results, there 
is no conclusive evidence of the effect of PRP on tissue healing13 
and one of the reasons could be the lack of knowledge of the 
basic characteristics of PRP, as the number of platelets required, 
and the need for activation of these platelets.3
PRP can be defined as a fraction of a volume of plasma that has 
a higher concentration of platelets than in peripheral blood.14,15 
Platelet concentration and amount of growth factors in the PRP 
depend on the technique used,16 but  on average, PRP has 
3-5 times more growth factors than peripheral blood.17 Today 
there are several techniques to obtain PRP and this has led 
to confusion regarding the classification,17-19 the time and the 
centrifugation speed, which are extremely variable.18
The use of PRP for tissue regeneration has grown, but it still 
needs further research and clarification regarding methods of 
its obtention20. The aim of this study is to demonstrate a new 
manual method of obtaining PRP.
MATERIALS AND METhODS
This study was approved by the Ethics Committee and was 
conducted in accordance with the ethical standards establi-
shed by the Helsinki Declaration of 1964. All subjects who 
underwent knee surgery at our institution who received PRP 
were included in this study. All subjects gave informed con-
sent before inclusion in the study. Data were collected from 
2008 to 2010.
For this study 61 ml of peripheral blood was collected from 
each patient. One milliliter was used to count the number of 
platelets and leukocytes in the peripheral blood and 60 ml 
were used to obtain PRP. Five milliliters of the anticoagulant 
sodium citrate were used and centrifugation at 541g for 5 
minutes (Centribio 80-2B centrifuge Centribio, São Paulo, SP, 
Brazil) to obtain 18ml of PRP and 14ml of poor platelet plasma. 
(Figures 1 and 2) Centrifugation separates blood into three 
components: red blood cells, buffy coat and PRP. PRP and 
buffy coat are carefully collected to prevent any contamination 
with red blood cells.
Samples of whole blood and PRP were sent to the hospital 
laboratory and platelets and leukocytes were quantified with a 
Sysmex - XT1800i hematology analyzer (Sysmex America, Inc., 
Mundelein, Illinois).
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Table 1 shows the distribution of platelets and leukocytes, 
divided by different age groups. Post- hoc analysis us-
ing Dunn‘s multiple comparison showed differences in the
following groups: 
a) Platelets in whole blood: 20-29 vs. 50-59 (p = 0,022), 20-29 
vs. > = 70 (p = 0,026), 40-49 vs. 50-59 (p = 0,007), 40-49 
vs. 60-69 (p = 0,027) e 40-49 vs. > = 70 (p = 0,017); 
b) Leucocytes in whole blood: 20-29 vs. 50-59 (p = 0,03), 30-39 
vs. 50-59 (p < 0,001), 30-39 vs. 60-69 (p=0,043), 30-39 vs. 
> = 70 (p = 0,017) e 40-49 vs. 50-59 (p = 0,003); 
c) Leucocytes in PRP: 20-29 vs. 50-59 (p < 0,001), 30-39 vs. 
50-59 (p = 0,015) e 40-49 vs. 50-59 (p < 0,001).
Table 1. Distribution of platelets and leukocytes in whole blood and in 








< 20 224.000 129.000 283.000 20
0,032
20 - 29 226.000 125.000 363.000 83
30 - 39 217.500 139.000 335.000 122
40 - 49 226.500 112.000 412.000 148
50 - 59 210.500 107.000 364.000 136
60 - 69 208.500 127.000 393.000 84
> = 70 202.000 101.000 346.000 39
Platelets in PRP 
(platelets/mm3)
< 20 597.500 429.000 835.000 20
0,199
20 - 29 627.000 216.000 1.178.000 83
30 - 39 604.500 248.000 1.156.000 122
40 - 49 636.000 304.000 1.615.000 148
50 - 59 621.500 203.000 1.229.000 136
60 - 69 580.500 301.000 1.686.000 84




< 20 6.555 4.610 9.000 12
0,001
20 - 29 6.810 4.090 15.280 57
30 - 39 7.100 4.290 15.960 87
40 - 49 6.880 3.700 79.990 114
50 - 59 6.230 2.660 9.360 95
60 - 69 6.500 4.200 14.860 57




< 20 12.010 9.800 17.100 12
0,002
20 - 29 14.100 3.960 36.040 63
30 - 39 13.010 3.250 39.860 95
40 - 49 13.700 3.830 209.020 118
50 - 59 10.830 4.110 28.500 102
60 - 69 12.550 4.440 32.200 66
> = 70 11.200 5.500 140.700 28
Figure 1. Platelet poor plasma (right) and platelet rich plasma (left).
Figure 2. Platelet rich plasma clot activated with autologous thrombin and 
10% calcium gluconate. 
STATISTICAL ANALySIS
Statistics data was calculated using a statistical software SPSS 
version 17.0 (SPSS Inc., Chicago, IL, USA). The Wilcoxon test 
was used to compare values pre-and post-centrifugation. The 
Mann-Whitney and Kruskal-Wallis tests were used to compare 
the difference between groups. Dunn’s multiple comparison 
was used as post hoc test. Data are presented as mean ± 
standard deviation. Statistical significance was set at 0.05.
RESULTS
A sample of 637 subjects was evaluated. Of these, 637 had 
the number of platelets in peripheral blood quantified, and 445 
had the number of leukocytes quantified in peripheral blood 
and in PRP. The mean age was 45.78 ± 15.11 years old and 
75% were male.
The mean platelet count and leukocytes in peripheral blood was 
220.377 ± 51.484/mm³ e 7.149 ± 4.777/mm³, respectively, while 
the number of platelets and leukocytes in PRP was 637.388 ± 
189.962/mm³ and 14.056 ± 11.820/mm³ (p < .001 for both).
The efficiency of platelet capture21 (PRP volume x [platelets 
PRP] / (blood volume x [blood platelets]) was 86.77% and 
the increase in the concentration of platelet factor was 2.89 
times. The increase in the leukocyte concentration factor was 
1.97 times.
In males, the mean platelet count in whole blood was 214,184 
± 49.732/mm³ and in PRP it was 626,718 ± 191.917/mm
(p < 0.001) whereas in females these values were, respec-
tively, 238.994 ± 52.327/mm³ and 669.465 ± 180.778/mm³ 
(p < 0,001). The difference between genders was statistically 
significant for counts in whole blood (p < 0.001) and for PRP 
count (p=0.005).
DISCUSSION
This study demonstrates the variability in the number of pla-
telets and leukocytes in peripheral blood and PRP in a large 
population. We also show that the method described herein 
shows an increased concentration factor of platelets and leu-
kocytes, and that there is high platelet collection efficiency. We 
also demonstrated significant difference in platelet count when 
comparing different ages and gender, since females showed 
a significantly higher amount than men, and younger people 
showed higher platelets and leukocytes count.
The use of growth factors as a stimulus for tissue healing 
has been studied in several areas of orthopedic and dentistry 
surgery.3-5,22 In Orthopedics, it has been successfully used in 
bone soft tissue healing procedures, in the reconstruction of 
the anterior cruciate ligament rupture, in Achilles tendon rupture 
in athletes, and in surgical scar after total knee arthroplasty.3 
Platelet rich plasma platelet poor plasma
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(Figure 3) Nevertheless, we have no conclusive evidence on the 
effect of PRP on the results obtained,3 and we do not know yet 
the best method for PRP application.6
A previous study from Castillo et al.21 compared three auto-
mated methods to obtain PRP. The highest platelet capture 
efficiency was obtained with Cascade MTF, and it was of 67.6%, 
a value lower than our study’s (86.77%). This may be due to 
the large volume of the obtained PRP (18 mL). Moreover, we 
had a high incremental factor, showing that this manual me-
thod may be used to obtain PRP. Obtaining PRP by automated 
methods is expensive,23 and can be prohibitive in developing 
countries, like ours. The use of a manual centrifuge, available 
Figure 3. Examples of clinical application of PRP: A) Placement of PRP in 
autograft to be used for reconstruction of the anterior cruciate ligament; 
B) Soaked autograft wrapped in gauze soaked with PRP. C) Application 
of PRP after knee arthroscopy.
in most hospitals and surgical centers, can make this method 
more available and ready to use. Thus, PRP can become a 
cheaper source of growth factors (PDGF, TGF-β, VEGF, IGF-1, 
etc.) and can stimulate the tissue healing.6,7 Castillo et al.21 
also measured the amount of white blood cells and found no 
difference between whole blood and PRP. This result is different 
from ours, since we found significant differences (p < 0.001) for 
leucocytes. This may be a result of the manual method used in 
this study, where the buffy coat was intentionally included in the 
preparation of the PRP. A highest concentration of leukocytes 
can lead to a higher concentration of PDGF (platelet growth 
factor)11 and this is an important growth factor for tissue rege-
neration, since it is a potent stimulator of mesenchymal cells 
(fibroblasts, smooth muscle cells) mitogenesis24 in addition to 
stimulating angiogenesis and macrophage activation.15 The 
presence of leukocytes may increase the anti-microbial activity 
of PRP as well as analgesia.19
There is still much confusion regarding the classification of PRP. 
Dohan Ehrenfest et al.18 suggested the following classification: 
leukocyte poor PRP; platelet and leukocyte rich plasma; platelet 
rich and leukocyte poor fibrin; and platelet and leukocyte rich 
fibrin. We believe that PRP obtained by the method described in 
this study is the platelet and leukocyte rich plasma, as there was 
a large incremental factor for both, platelets and leukocytes.
CONCLUSION
The method described herein produces platelet and leukocyte 
rich plasma with high leukocyte and platelet incremental factor.
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